OraSure decline creates long-term buying opportunity, says Barrington After OraSure reported weaker than expected Q3 results and provided weaker than expected Q4 guidance, Barrington expects the company to start rapidly penetrating the HCV and HIV markets. The firm maintains a $12.50 target and Outperform rating.
CLDF teams with Walgreens to offer OraSure HCV test for free The Chronic Liver Disease Foundation announced earlier that it's collaborating with Walgreens (WBA) to offer free hepatitis C testing with the OraQuick HCV Rapid Test at more than 60 Walgreens retail pharmacies in 12 cities throughout the country. The program, which is slated to launch this August and run through January 2016, will offer free rapid HCV testing on specific days and times each week to patients at risk for HCV. The test is made by OraSure (OSUR).
UBS to hold a conference Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link